RSV Antibodies with Optimized CDR Sequences for Broad Subtype Protection

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for Respiratory Syncytial Virus (RSV) infection, such as antiviral therapies and monoclonal antibodies like Palivizumab, are either ineffective or provide limited prophylactic coverage, highlighting the need for alternative and improved antibodies against RSV.

Innovation Solution

Development of synthetic, recombinant, or isolated antibodies or functional parts thereof that specifically bind to RSV, characterized by specific heavy and light chain variable region CDR sequences, which provide improved binding affinity and protective efficacy against RSV infection.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If Palivizumab is used for prophylaxis against RSV infection, then protection against RSV is achieved, but the coverage is limited and alternative antibodies are needed

Engineering Contradiction:

Improveprophylactic coverageVSAvoidcoverage against RSV subtypes

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent develops antibody variants with improved binding properties that provide broader coverage against multiple RSV subtypes (A and B), making the antibody treatment more universal and versatile compared to Palivizumab's limited coverage

Inventive Principle:

Principle #6Universality (Multi-functionality)

2Reliability

If existing monoclonal antibodies are used, then some protection is provided, but binding affinity and neutralization capability are insufficient

Engineering Contradiction:

Improveprotective efficacyVSAvoidbinding affinity

Core Design Contradiction:

ReliabilityVSManufacturing precision

Solution Approach 1:

The patent employs systematic mutations of amino acid residues in the antibody variable regions to optimize binding affinity and neutralization capability, achieving improved protective efficacy through precise parameter changes in the antibody structure

Inventive Principle:

Principle #35Parameter changes

3Ease of manufacture

If antiviral therapies such as Ribavirin are used, then treatment is provided, but effectiveness in RSV infection is not proven

Engineering Contradiction:

Improvetreatment availabilityVSAvoidtreatment effectiveness

Core Design Contradiction:

Ease of manufactureVSReliability

Solution Approach 1:

The patent replaces antiviral drug therapy (chemical mechanism) with monoclonal antibody therapy (biological mechanism), providing a more effective treatment approach through high-affinity binding and neutralization of RSV

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The proposed antibodies demonstrate enhanced protection against RSV A and B subtypes, improved neutralization capabilities, and lower IC50 values, indicating strong affinity and effectiveness in counteracting RSV infections.

Implementation Method 1

a synthetic, recombinant, or isolated antibody or a functional part thereof capable of specifically binding Respiratory Syncytial Virus

Methodology Applied

Scientific EffectAntibody-antigen binding: Adsorption

Data Source

PatentUS20250179153A1RSV-specific antibodies and functional parts thereof

Publication Date: 2025.06.05 MEDIMMUNE LTD

AI summary

This application provides antibodies and functional equivalents thereof which are capable of specifically binding RSV, as well as means and methods for producing them.